IN VITRO AND IN SILICO STUDIES ON EVALUATING EREMANTHIN AS POTENTIAL THERAPEUTIC DRUG AGAINST BREAST CANCER

  • ANITA ROY A Bioinformatics Centre (BIF), Department of Biotechnology and Bioinformatics, Holy Cross College (Autonomous), Tiruchirappalli, Tamil Nadu, India.
  • ANGEL MARY Bioinformatics Centre (BIF), Department of Biotechnology and Bioinformatics, Holy Cross College (Autonomous), Tiruchirappalli, Tamil Nadu, India.
  • INDU SABAPATHY Bioinformatics Centre (BIF), Department of Biotechnology and Bioinformatics, Holy Cross College (Autonomous), Tiruchirappalli, Tamil Nadu, India.
  • MANIKKAM RAJALAKSHMI Bioinformatics Centre (BIF), Department of Biotechnology and Bioinformatics, Holy Cross College (Autonomous), Tiruchirappalli, Tamil Nadu, India.

Abstract

Objective: The present study was aimed to evaluate the anticancer property of eremanthin isolated from Costus speciosus against breast cancer using in vitro and in silico approaches and thereby to develop eremanthin as a typical phytotherapeutic drug against cancer.


Methods: The presence of specific biologically active extract was confirmed under GC–MS/MS (gas chromatography–mass spectrometry) analysis. The cell proliferation inhibitory effect of the eremanthin was confirmed by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) and LDH (lactate dehydrogenase) assay. In silico studies were performed to predict the targeted interaction of eremanthin with cancer proteins.


Results: The GC–MS/MS analysis confirmed the presence of eremanthin with peak value of RA: 20.03. The MTT and LDH assays revealed the antiproliferative activity of eremanthin on MCF-7 and MDA-MB-231 breast cancer cell lines. The results provide stable interaction between eremanthin and cancer target proteins.


Conclusion: Thus, the compound can be used as an effective herbal therapeutic molecule to treat cancer with further explorations.

Keywords: Costus speciosus, Eremanthin, Cancer, Molecular docking

References

1. Haber DH. Roads leading to breast cancer. N Engl J Med 2001;343:1566-8.
2. Alison MR. Hand Book on Cancer. London, UK: Imperial College School of Medicine; 2001.
3. Dechant KL, Brogden RN, Pilkington T, Faulds D. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 1991;42:428-67.
4. Kamboj VP. Herbal medicine. Curr Sci 2000;78:35-51.
5. Cragg GM, Kingston DG, Newman DJ. Anticancer Agents from Natural Products. Boca Raton, FL: Brunner-Routledge Psychology Press, Taylor and Francis Group; 2005.
6. Sari IP, Nurrochmad A. Sub-acute toxicity study of ethanolic extract of pacing (Costus speciosus) in male mice. Int J Pharm Pharm Sci 2016;8:97-101.
7. Upadhyay HC, Saini DC, Srivastava SK. Phytochemical analysis of Ammannia multiflora. Res J Phytochem 2011;5:170-6.
8. Kala C, Ali SS, Chaudhary S. Comparative phamacognostical evaluation of Costus speciosus (wild ginger) and Zingiber officinale (ginger) rhizome. Int J Curr Pharm Res 2016;8:19-23.
9. Eliza J, Daisy P, Ignacimuthu S. Antioxidant activity of eremanthin and eremanthin isolated from Costus speciosus (Koen ex. Retz) Sm. Chem Biol Interact 2010;88:467-72.
10. Richter M, Zhang H. Receptor-targeted cancer therapy. DNA Cell Biol 2005;24:271-82.
11. Aja PM, Okaka AN, Onu PN, Ibiam U, Urako AJ. Phytochemical composition of Talinum triangulare (water leaf) leaves. Pak J Nutr 2010;9:527-30.
12. Berman H, Henrick K, Nakamura H, Markley JL. The worldwide protein data bank (wwPDB): Ensuring a single, uniform archive of PDB data. Nucleic Acids Res 2006;35:D301-3.
13. Cosa P, Vlietinck AJ, Berghe DV, Maes L. Anti-infective potential of natural products: How to develop a stronger in vitro “proof-of-concept”. J Ethnopharmacol 2006;106:290-302.
14. Khoja KK, Shaf G, Hasan TN, Syed N, Al-Khalifa AS, Al-Assaf AH, et al. Fenugreek, a naturally occurring edible spice, kills MCF-7 human breast cancer cells via an apoptotic pathway. Asian Pac J Cancer Prev 2011;12:3299-304.
15. Jang M, Kim SS, Lee J. Cancer cell metabolism: Implications for therapeutic targets. Exp Mol Med 2013;45:e45.
16. Ludas A, Indu S, Hinduja S, Nirmala AK, Rajalakshmi M. Antioxidant potential of polysaccharide isolated from methanolic extract of Tinospora cordifolia stem bark. Asian J Pharm Clin Res 2018;11:447-51.
17. Reddy MN, Reddy RN, Jamil K. Spicy anti-cancer spices: A review. Int J Pharm Pharm Sci 2015;7:1-6.
18. Nerurkar P, Ray RB. Bitter melon: Antagonist to cancer. Pharm Res 2010;27:1049-53.
19. Decker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 1988;115:61-9.
20. Compeau D, Higgins CA, Huff S. Social cognitive theory and individual reactions to computing technology: A longitudinal study. MIS Q 1999;23:145-58.
21. Mcconkey K, Drake D, Meehan H, Parsons N. Husking stations provide evidence of seed predation by introduced rodents in Tongan rain forests. Biol Conserv 2003;109:221-5.
22. Al-Nadaf AH, Taha MO, Aldal’in HK. Haloperidol inhibits Memapsin 2: Innovation by docking simulation and in vitro assay. Pak J Pharm Sci 2015;28:139-46.
23. Pitchai D, Roy A, Banu S. In vitro and in silico evaluation of NF ?B targeted costunolide action on estrogen receptor-negative breast cancer cells a comparison with normal breast cells. Phytother Res 2014;28:1499-505.
Statistics
20 Views | 21 Downloads
Citatons
How to Cite
A, A. R., A. MARY, I. SABAPATHY, and M. RAJALAKSHMI. “IN VITRO AND IN SILICO STUDIES ON EVALUATING EREMANTHIN AS POTENTIAL THERAPEUTIC DRUG AGAINST BREAST CANCER”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 13, no. 10, Aug. 2020, pp. 132-7, doi:10.22159/ajpcr.2020.v13i10.36818.
Section
Original Article(s)